The Novo Nordisk company has decided to become its main spot, because it sees Albero as a person "with a tremendous determination, which serves as an example to show that diabetes, well controlled, is not an obstacle."
Daniel Albero made history in January 2019 by becoming the first pilot with type 1 diabetes to play the Dakar Rally, where he managed to reach the fourth stage in Peruvian territory before retiring due to mechanical problems.
A year later, the appointment will change territory to cross, in January 2020, the sands of Saudi Arabia.And the Valencian has continued to prepare at the physical and piloting level waiting to face the appointment with greater guarantees than in his first participation.
The pharmaceutical company Novo Nordisk contributed to Daniel's first adventure as part of the firms that bet on him.And, after valuing his experience, his courage and his attitude during the first foray into the Dakar, he has decided to become his main spotter.
The company sees Albero as a person "with a tremendous determination, which serves as an example to show that diabetes, well controlled, is not an obstacle not only to make a normal life, but to face challenges of different consideration and fight for thatthat is longed for.
It should be remembered that Novo Nordisk already has extensive experience in high competition sport, since, for several years, he has supported a professional cycling team composed in full by athletes with diabetes.
